Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $19.80 Consensus Target Price from Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $19.80.

A number of equities research analysts have issued reports on BCYC shares. Citigroup reiterated an “outperform” rating on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Royal Bank Of Canada reiterated a “sector perform” rating and set a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Oppenheimer reissued an “outperform” rating and set a $44.00 price objective (down previously from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Citizens Jmp upped their target price on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the completion of the sale, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at $3,997,357.10. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 8,527 shares of company stock valued at $71,738 in the last ninety days. 22.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Long Focus Capital Management LLC increased its position in Bicycle Therapeutics by 138.2% during the first quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock worth $10,984,000 after buying an additional 750,661 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Bicycle Therapeutics by 454.1% during the 2nd quarter. Acadian Asset Management LLC now owns 698,501 shares of the company’s stock worth $4,840,000 after acquiring an additional 572,439 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Bicycle Therapeutics by 21.7% during the 1st quarter. Armistice Capital LLC now owns 2,672,000 shares of the company’s stock valued at $22,685,000 after acquiring an additional 476,000 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Bicycle Therapeutics by 64.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock valued at $8,889,000 after acquiring an additional 451,135 shares in the last quarter. Finally, Tybourne Capital Management HK Ltd. raised its stake in shares of Bicycle Therapeutics by 72.4% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after acquiring an additional 417,400 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Down 1.1%

Shares of NASDAQ BCYC opened at $6.44 on Thursday. Bicycle Therapeutics has a one year low of $6.10 and a one year high of $25.39. The business has a 50-day moving average price of $7.61 and a two-hundred day moving average price of $7.84. The firm has a market capitalization of $446.36 million, a PE ratio of -1.78 and a beta of 1.48.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The company had revenue of $2.90 million during the quarter, compared to analysts’ expectations of $9.43 million. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%. Research analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.